Samulitis BK - Search Results

1

Characterization of a membrane-active anti-tumor agent, UA8967.

Dorr RT, Samulitis BK, Wisner L, Han H, Zhao Y, Beroza P, Damodaran K, Igarashi S, Landowski TH, Von Hoff DD. Dorr RT, et al. Among authors: samulitis bk. Invest New Drugs. 2013 Jun;31(3):576-86. doi: 10.1007/s10637-012-9901-z. Epub 2012 Nov 23. Invest New Drugs. 2013. PMID: 23179338 Free PMC article.

2

Correlates of imexon sensitivity in human multiple myeloma cell lines.

Samulitis BK, Landowski TH, Dorr RT. Samulitis BK, et al. Leuk Lymphoma. 2006 Jan;47(1):97-109. doi: 10.1080/10428190500266210. Leuk Lymphoma. 2006. PMID: 16321833

3

Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.

Samulitis BK, Landowski TH, Dorr RT. Samulitis BK, et al. Invest New Drugs. 2009 Feb;27(1):89-98. doi: 10.1007/s10637-008-9149-9. Epub 2008 Jul 8. Invest New Drugs. 2009. PMID: 18607542 Free PMC article.

4

Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.

Dorr RT, Wisner L, Samulitis BK, Landowski TH, Remers WA. Dorr RT, et al. Among authors: samulitis bk. Cancer Chemother Pharmacol. 2012 Apr;69(4):1039-49. doi: 10.1007/s00280-011-1784-8. Epub 2011 Dec 21. Cancer Chemother Pharmacol. 2012. PMID: 22186884 Free PMC article.

5

The diaryl oxazole PC-046 is a tubulin-binding agent with experimental anti-tumor efficacy in hematologic cancers.

Landowski TH, Samulitis BK, Dorr RT. Landowski TH, et al. Among authors: samulitis bk. Invest New Drugs. 2013 Dec;31(6):1616-25. doi: 10.1007/s10637-013-0019-8. Epub 2013 Sep 14. Invest New Drugs. 2013. PMID: 24037082 Free PMC article.

6

Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.

Scott J, Dorr RT, Samulitis B, Landowski TH. Scott J, et al. Cancer Chemother Pharmacol. 2007 May;59(6):749-57. doi: 10.1007/s00280-006-0329-z. Epub 2007 Feb 28. Cancer Chemother Pharmacol. 2007. PMID: 17333195 Free PMC article.

7

Characterization of novel diaryl oxazole-based compounds as potential agents to treat pancreatic cancer.

Shaw AY, Henderson MC, Flynn G, Samulitis B, Han H, Stratton SP, Chow HH, Hurley LH, Dorr RT. Shaw AY, et al. J Pharmacol Exp Ther. 2009 Nov;331(2):636-47. doi: 10.1124/jpet.109.156406. Epub 2009 Aug 5. J Pharmacol Exp Ther. 2009. PMID: 19657049 Free PMC article.

8

Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.

Roman NO, Samulitis BK, Wisner L, Landowski TH, Dorr RT. Roman NO, et al. Among authors: samulitis bk. Cancer Chemother Pharmacol. 2011 Jan;67(1):183-92. doi: 10.1007/s00280-010-1306-0. Epub 2010 Mar 26. Cancer Chemother Pharmacol. 2011. PMID: 20339847 Free PMC article.

9

Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.

Samulitis BK, Dorr RT, Chow HH. Samulitis BK, et al. Anticancer Res. 2011 Sep;31(9):2781-5. Anticancer Res. 2011. PMID: 21868520

10

Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.

Sheveleva EV, Landowski TH, Samulitis BK, Bartholomeusz G, Powis G, Dorr RT. Sheveleva EV, et al. Among authors: samulitis bk. Mol Cancer Res. 2012 Mar;10(3):392-400. doi: 10.1158/1541-7786.MCR-11-0359. Epub 2012 Jan 24. Mol Cancer Res. 2012. PMID: 22275514 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17 results

Search Page

Filters